New scoring system to create a prognostic criteria in colorectal carcinoma based on serum elevation of C-reactive...

Area of Science:

• Oncology
• Clinical Pathology
• Biomarkers

Background:

• Elevated C-reactive protein (CRP) and reduced lymphocytes are linked to tumor malignancy.
• These markers suggest potential for cancer progression.

Purpose of the Study:

• To evaluate the prognostic value of a new CRP/Lymphocyte Score (CLS) in colorectal carcinoma.
• To determine if CLS can indicate progressive potential in surgically treated patients.

Main Methods:

• A study involving 280 surgically treated colorectal carcinoma patients.
• Analysis of serum CRP levels and peripheral blood lymphocyte percentages to calculate CLS.
• Survival analysis and multivariate analysis were performed.

Main Results:

• Significant survival differences were observed based on CLS categories (0, 1, and 2).
• Multivariate analysis identified CLS, histologic type, and tumor stage as independent prognostic factors for worse outcomes.
• CLS was a highly significant predictor (P < 0.0001).

Conclusions:

• The newly developed CLS serves as an independent prognostic indicator for colorectal carcinoma.
• CLS can be a valuable tool for providing prognostic information to clinicians.
• This score aids in assessing patient prognosis and guiding treatment strategies.